GMTX Research and Charts

GMTX - Gemini Therapeutics Inc Ordinary Shares (Healthcare: Biotechnology)

Projected Earnings Date: 0000-02-29 (Delayed quote data 2025-06-26)

Last 54.13	Change ⇑ +0.21 (+0.39%)	Volume 220,107
	Open 53.98	High 54.36	Low 52.80

8EMA (Daily) 52.83	40EMA (Daily) 49.75	50EMA (Daily) 49.55	STO (Daily) 81.437	MACD Hist (Daily) 0.584
8EMA (Weekly) 50.586	40EMA (Weekly) 51.00	50EMA (Weekly) 50.77	STO (Weekly) 81.322	MACD Hist (Weekly) 1.724


Company Profile
Gemini Therapeutics Inc is a clinical-stage precision medicine company developing novel therapeutic compounds to treat genetically defined AMD. Its candidate, GEM103, is a recombinant form of the Complement Factor H protein (CFH) and is designed to address both complement hyperactivity and restore retinal health. Variations in the gene that encodes CFH strongly correlate with an increased risk of developing AMD.

Disclaimer: All information provided is for informational purposes only and not intended for trading purposes or advice. The quotes and charts are not real time and have delays of at least 20 minutes. Data accuracy cannot be guaranteed as errors will occur. Please do not rely on the above information to make your stock/option trades. Neither OptionChance.com nor any of independent data providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein.